The role of dopaminergic mechanisms in naloxone-induced inhibition of apomorphine-induced stereotyped behavior. 1980

B H Moon, and J J Feigenbaum, and P E Carson, and H L Klawans

UI MeSH Term Description Entries
D008297 Male Males
D009270 Naloxone A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. MRZ 2593-Br,MRZ-2593,Nalone,Naloxon Curamed,Naloxon-Ratiopharm,Naloxone Abello,Naloxone Hydrobromide,Naloxone Hydrochloride,Naloxone Hydrochloride Dihydride,Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Narcan,Narcanti,Abello, Naloxone,Curamed, Naloxon,Dihydride, Naloxone Hydrochloride,Hydrobromide, Naloxone,Hydrochloride Dihydride, Naloxone,Hydrochloride, Naloxone,MRZ 2593,MRZ 2593 Br,MRZ 2593Br,MRZ2593,Naloxon Ratiopharm
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001058 Apomorphine A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use. Apokinon,Apomorphin-Teclapharm,Apomorphine Chloride,Apomorphine Hydrochloride,Apomorphine Hydrochloride Anhydrous,Apomorphine Hydrochloride, Anhydrous,Apomorphine Hydrochloride, Hemihydrate,Britaject,Apomorphin Teclapharm
D001519 Behavior The observable response of a man or animal to a situation. Acceptance Process,Acceptance Processes,Behaviors,Process, Acceptance,Processes, Acceptance

Related Publications

B H Moon, and J J Feigenbaum, and P E Carson, and H L Klawans
January 1975, Brain, behavior and evolution,
B H Moon, and J J Feigenbaum, and P E Carson, and H L Klawans
September 1979, Journal of the neurological sciences,
B H Moon, and J J Feigenbaum, and P E Carson, and H L Klawans
February 1987, Brain research,
B H Moon, and J J Feigenbaum, and P E Carson, and H L Klawans
May 1997, Progress in neuro-psychopharmacology & biological psychiatry,
B H Moon, and J J Feigenbaum, and P E Carson, and H L Klawans
October 1973, European journal of pharmacology,
B H Moon, and J J Feigenbaum, and P E Carson, and H L Klawans
November 1981, Pharmacology, biochemistry, and behavior,
B H Moon, and J J Feigenbaum, and P E Carson, and H L Klawans
April 1974, The Journal of pharmacy and pharmacology,
B H Moon, and J J Feigenbaum, and P E Carson, and H L Klawans
September 1999, Psychopharmacology,
B H Moon, and J J Feigenbaum, and P E Carson, and H L Klawans
January 1978, Communications in psychopharmacology,
B H Moon, and J J Feigenbaum, and P E Carson, and H L Klawans
April 1974, Life sciences,
Copied contents to your clipboard!